Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
URLC10 peptide vaccine
- Development stage
- Unknown
- Lead developer
- Juntendo School of Medicine
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
A cancer peptide vaccine containing epitopes derived from the tumor antigen up-regulated lung cancer 10 (URLC10), and in some formulations also from CDCA1 (cell division cycle-associated protein 1) and KOC1 (IGF II mRNA binding protein 3). The primary mechanism is to stimulate a cytotoxic T lymphocyte response against tumor cells expressing these antigens, leading to cell lysis and decreased tumor growth. The vaccine has been studied primarily for advanced gastric cancer refractory to chemotherapy. It is typically administered subcutaneously with adjuvants such as Montanide ISA51 or GM-CSF. Clinical trials have demonstrated safety and immunogenicity in humans.
- Other names
- up-regulated lung cancer 10 peptide vaccineURLC10/Montanide ISA51 vaccine
02
Targets
LY6K (Lymphocyte antigen 6 complex locus protein K)NUF2 (Cell division cycle associated 1 protein)LCAA (Lung Cancer-Associated Antigen L523S)
Beyond the preview
Go deeper on URLC10 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on URLC10 peptide vaccine.